Britannia Pharmaceuticals’ apomorphine shows promise in Phase 3 TOLEDO trial for Parkinson’s disease

Britannia Pharmaceuticals, a subsidiary of the British pharma group, has announced successful Phase 3 results for its APO-go/MOVAPO (apomorphine) subcutaneous infusion, marking a significant advancement ... Read More